• SENSEX
    NIFTY 50
Healthcare

Gilead disputes report that its drug flopped in leaked coronavirus trial

Updated : April 24, 2020 07:46 AM IST

The rate of death was similar at 13.9 percent for remdesivir versus 12.8 percent in the control group.
Gilead shares closed down 4.3 percent after the data was inadvertently released.
Gilead disputes report that its drug flopped in leaked coronavirus trial

You May Also Like

Live TV
Advertisement